Cervical Cancer Screening Rates Declining in Younger Women
By HospiMedica International staff writers Posted on 21 Jan 2019 |
Image: A disparity exists between self-reported and actual CVC screening (Photo courtesy of Corbis).
A new study concludes that the percentage of women screened for cervical cancer (CVC) may be far lower than self-reported data suggests.
Researchers at the Mayo Clinic (Rochester, MN, USA) conducted an epidemiologic study in order to assess implementation of the 2012 U.S. CVC screening recommendations, which recommend Papanicolaou (PAP) testing every three years for women 21–65 years of age, or PAP–human papillomavirus (PAP-HPV) co-testing at five year intervals for women 30–65 years of age. A secondary aim was to assess sociodemographic factors correlating with screening. The study population included women 16 years and older living in Olmsted County (MN, USA).
Rochester Epidemiology Project data was collected yearly from 2005 (47,203 participants) through 2016 (49,510 participants). Significant declines in PAP completion rates over time were observed in all age groups, including an unexpected decline in women 21- 29 year of age. Coincident with decreasing PAP screening rates, PAP-HPV co-testing significantly increased among women age 30–65 years, from 10% in 2007 to 60.8% in 2016, with 64.6% of women 30-65-years of age up to date with CVC screening. The study was published on January 9, 2018, in the Journal of Women's Health.
“These cervical cancer rates are unacceptably low. Routine screening every three years with a PAP test or every five years with a PAP-HPV co-test ensures precancerous changes are caught early and may be followed more closely or treated,” said lead author Kathy MacLaughlin, MD. “African-American women were 50% less likely to be up-to-date on CVC screening than white woman, and Asian women were nearly 30% less likely to be current on screening. These racial disparities are especially concerning.”
PAP-HPV co-testing has a lower false negative rate than PAP testing alone, as it reduces the likelihood of missing an anomaly and improves detection of glandular cell abnormalities. Despite these benefits, the study results indicate that actual screening rates are substantially lower than the 81% compliance rate self-reported in the 2015 National Health Interview Survey.
Related Links:
Mayo Clinic
Researchers at the Mayo Clinic (Rochester, MN, USA) conducted an epidemiologic study in order to assess implementation of the 2012 U.S. CVC screening recommendations, which recommend Papanicolaou (PAP) testing every three years for women 21–65 years of age, or PAP–human papillomavirus (PAP-HPV) co-testing at five year intervals for women 30–65 years of age. A secondary aim was to assess sociodemographic factors correlating with screening. The study population included women 16 years and older living in Olmsted County (MN, USA).
Rochester Epidemiology Project data was collected yearly from 2005 (47,203 participants) through 2016 (49,510 participants). Significant declines in PAP completion rates over time were observed in all age groups, including an unexpected decline in women 21- 29 year of age. Coincident with decreasing PAP screening rates, PAP-HPV co-testing significantly increased among women age 30–65 years, from 10% in 2007 to 60.8% in 2016, with 64.6% of women 30-65-years of age up to date with CVC screening. The study was published on January 9, 2018, in the Journal of Women's Health.
“These cervical cancer rates are unacceptably low. Routine screening every three years with a PAP test or every five years with a PAP-HPV co-test ensures precancerous changes are caught early and may be followed more closely or treated,” said lead author Kathy MacLaughlin, MD. “African-American women were 50% less likely to be up-to-date on CVC screening than white woman, and Asian women were nearly 30% less likely to be current on screening. These racial disparities are especially concerning.”
PAP-HPV co-testing has a lower false negative rate than PAP testing alone, as it reduces the likelihood of missing an anomaly and improves detection of glandular cell abnormalities. Despite these benefits, the study results indicate that actual screening rates are substantially lower than the 81% compliance rate self-reported in the 2015 National Health Interview Survey.
Related Links:
Mayo Clinic
Latest Patient Care News
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
- Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases
- Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest
- World's First AI-Ready Infrasound Stethoscope Listens to Bodily Sounds Not Audible to Human Ear